As Lgr5+ stem cells are the cell of origin for intestinal cancer and also a marker of intestinal cancer stem cells, this data opens new avenues of research to determine the therapeutic benefit of inhibiting Fzd7 to specifically target these cells. Here, LGR5 is linked to intestinal cancer.